It has previously been reported that ADA treatment decreased serum levels of vascular cell adhesion molecule 1, a biomarker of cardiovascular diseases, in patients with plaque psoriasis [22], indicating the cardioprotective effects of ADA. The gene discussed is VCAM1; the disease is psoriasis vulgaris.